208 related articles for article (PubMed ID: 23683497)
21. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
Kumamoto K; Spillare EA; Fujita K; Horikawa I; Yamashita T; Appella E; Nagashima M; Takenoshita S; Yokota J; Harris CC
Cancer Res; 2008 May; 68(9):3193-203. PubMed ID: 18451145
[TBL] [Abstract][Full Text] [Related]
22. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
24. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
Arya AK; El-Fert A; Devling T; Eccles RM; Aslam MA; Rubbi CP; Vlatković N; Fenwick J; Lloyd BH; Sibson DR; Jones TM; Boyd MT
Br J Cancer; 2010 Jul; 103(2):186-95. PubMed ID: 20588277
[TBL] [Abstract][Full Text] [Related]
25. 1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.
Chen L; Yang R; Qiao W; Zhang W; Chen J; Mao L; Goltzman D; Miao D
Aging Cell; 2019 Jun; 18(3):e12951. PubMed ID: 30907059
[TBL] [Abstract][Full Text] [Related]
26. Synaptotagmin-7, a binding protein of P53, inhibits the senescence and promotes the tumorigenicity of lung cancer cells.
Fei Z; Gao W; Xie R; Feng G; Chen X; Jiang Y
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647108
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
28. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
29. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
30. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
Duan L; Perez RE; Chen L; Blatter LA; Maki CG
J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
[TBL] [Abstract][Full Text] [Related]
31. Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro.
Yao GD; Yang J; Li XX; Song XY; Hayashi T; Tashiro SI; Onodera S; Song SJ; Ikejima T
Acta Pharmacol Sin; 2017 Oct; 38(10):1401-1411. PubMed ID: 28649131
[TBL] [Abstract][Full Text] [Related]
32. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
33. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
34. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
[TBL] [Abstract][Full Text] [Related]
35. The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.
Haferkamp S; Tran SL; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging (Albany NY); 2009 May; 1(6):542-56. PubMed ID: 20157537
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Xu X; Liu Q; Zhang C; Ren S; Xu L; Zhao Z; Dou H; Li P; Zhang X; Gong Y; Shao C
Cell Death Dis; 2019 Mar; 10(4):282. PubMed ID: 30910997
[TBL] [Abstract][Full Text] [Related]
37. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
38. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype.
Wiley CD; Schaum N; Alimirah F; Lopez-Dominguez JA; Orjalo AV; Scott G; Desprez PY; Benz C; Davalos AR; Campisi J
Sci Rep; 2018 Feb; 8(1):2410. PubMed ID: 29402901
[TBL] [Abstract][Full Text] [Related]
40. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.
Tsao CC; Corn PG
Cancer Biol Ther; 2010 Dec; 10(12):1315-25. PubMed ID: 20953142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
